Table 5.
Univariate regressions of NMR parameters and lupus history
| NMR parameters | SLEDAI (n=63) | SLICC (n=59) | Disease duration (n=64) | Protein/ creatinine ratio (n=55) |
Framingham risk (n=64) |
HOMA-IR (n=64) |
| Baseline parameters | ||||||
| Total cholesterol | −0.250 (0.049) | −0.072 (0.586) | −0.084 (0.509) | 0.111 (0.419) | 0.030 (0.814) | −0.011 (0.928) |
| Triglycerides | −0.008 (0.951) | −0.075 (0.570) | −0.095 (0.454) | 0.236 (0.083) | 0.138 (0.277) | 0.453 (<0.001) |
| HDL cholesterol | −0.231 (0.069) | −0.134 (0.312) | −0.021 (0.868) | −0.019 (0.890) | −0.237 (0.059) | −0.315 (0.011) |
| LDL cholesterol | −0.144 (0.260) | −0.017 (0.900) | −0.084 (0.509) | 0.050 (0.715) | 0.313 (0.301) | −0.013 (0.917) |
| VLDL triglycerides | 0.057 (0.657) | −0.059 (0.660) | −0.123 (0.332) | 0.280 (0.038) | 0.097 (0.445) | 0.521 (<0.001) |
| GlycA | 0.011 (0.934) | 0.331 (0.010) | 0.226 (0.073) | 0.226 (0.097) | 0.040 (0.752) | 0.407 (0.001) |
| Particle counts | ||||||
| HDL particle count | −0.345 (0.006) | −0.197 (0.135) | 0.001 (0.999) | 0.048 (0.728) | 0.002 (0.990) | −0.103 (0.418) |
| Small HDL particle count | −0.281 (0.026) | 0.012 (0.927) | −0.107 (0.402) | 0.101 (0.461) | 0.132 (0.300) | 0.144 (0.257) |
| Medium HDL particle count | 0.051 (0.691) | −0.155 (0.241) | 0.178 (0.159) | −0.043 (0.753) | 0.046 (0.721) | −0.038 (0.767) |
| Large HDL particle count | −0.085 (0.509) | −0.106 (0.424) | −0.046 (0.719) | −0.054 (0.694) | −0.286 (0.022) | −0.350 (0.005) |
| LDL particle count | −0.029 (0.822) | −0.036 (0.787) | −0.127 (0.318) | 0.109 (0.429) | 0.332 (0.007) | 0.180 (0.154) |
| Small LDL particle count | 0.127 (0.320) | −0.049 (0.712) | −0.036 (0.779) | 0.094 (0.496) | 0.403 (0.001) | 0.314 (0.012) |
| Large LDL particle count | −0.162 (0.203) | 0.010 (0.942) | −0.154 (0.225) | 0.044 (0.748) | −0.073 (0.567) | −0.158 (0.214) |
| IDL particle count | −0.130 (0.308) | 0.005 (0.971) | 0.083 (0.517) | −0.104 (0.451) | −0.104 (0.413) | −0.083 (0.515) |
| VLDL particle count | 0.048 (0.711) | −0.013 (0.924) | −0.170 (0.179) | 0.436 (0.001) | 0.013 (0.918) | 0.534 (<0.001) |
| Small VLDL particle count | 0.044 (0.730) | 0.051 (0.699) | −0.165 (0.193) | 0.498 (<0.001) | −0.078 (0.542) | 0.414 (<0.001) |
| Medium VLDL particle count | 0.016 (0.902) | −0.069 (0.605) | −0.101 (0.428) | 0.256 (0.059) | 0.069 (0.587) | 0.421 (<0.001) |
| Large medium VLDL particle count | 0.033 (0.797) | −0.074 (0.578) | −0.112 (0.380) | 0.247 (0.069) | 0.102 (0.424) | 0.457 (<0.001) |
| Large VLDL particle count | 0.084 (0.515) | −0.013 (0.921) | −0.066 (0.605) | 0.068 (0.622) | 0.194 (0.125) | 0.414 (0.001) |
| Particle size | ||||||
| HDL particle size | 0.011 (0.932) | −0.078 (0.557) | 0.056 (0.659) | −0.081 (0.554) | −0.329 (0.008) | −0.353 (0.004) |
| LDL particle size | −0.191 (0.133) | 0.030 (0.821) | 0.151 (0.237) | −0.129 (0.347) | −0.267 (0.033) | −0.316 (0.011) |
| VLDL particle size | −0.073 (0.569) | −0.036 (0.789) | 0.067 (0.600) | −0.182 (0.185) | 0.740 (0.580) | −0.003 (0.979) |
Univariate regressions reported as β-coefficient (p value).
Parameters reaching significance (p<0.05) highlighted in bold; after controlling for multiple comparisons only those with p<0.00009 remain statistically significant.
GlycA, glycoprotein acetylation; HDL, high-density lipoprotein; HOMA-IR, homoeostatic model assessment insulin resistance; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; NMR, nuclear MR; SLEDAI, SLE Disease Activity Index; SLICC, Systemic Lupus International Collaborating Committee; VLDL, very low-density lipoprotein.